ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

By sjmartinez • August 31, 2023

Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, Wohl DA, Daar ES, Hughes MD; ACTIV-2/A5401 Study Team. ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. J Infect Dis. 2023 Aug 31;228(Supplement_2):S77-S82. doi: 10.1093/infdis/jiad246. PMID: 37650231; PMCID: PMC10469341.

Tags: ACTIV-2, Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, Publications

Development of a Primary Care Cardio-Kidney Risk Navigator for Clinical Decision Support

Gluckman TJ, Birkeland K, Bhatt A, Budoff MJ, Danna SC, Desai NR, Norfolk E, Elbedewe A, Kiernan G, Pachpor R, Hirsch J. Development of a[...]

Predictive Value of Coronary Artery Calcium Score From Nongated Chest CT Scans Compared With Gated Scans and Incidence of Cardiovascular Events

Verghese D, Trujillo R, Abraham D, McClelland RL, Kinninger A, Manubolu S, Aldana J, Cubeddu RJ, Drachman D, Inglessis-Azuaje I, Wang DD, Fahed A, Brumback[...]

Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals

Abuknesha NR, O'Keefe JH, Qian F, Tintle NL, Lin Y, Sun Y, Qian HZ, Aisen PS, Albert CM, Aronson WJ, Asbeutah AAA, Bischoff-Ferrari HA, Budoff[...]